NCT01833741View on ClinicalTrials.gov

A Study of LUMIGAN® RC in the Clinical Setting

PHASE4CompletedINTERVENTIONAL

Enrollment

1,137

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Glaucoma, Primary Open AngleOcular Hypertension

Interventions

DRUG

Bimatoprost 0.01%

Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.

Trial Locations (1)

Unknown

Barrie

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Allergan

INDUSTRY

NCT01833741 - A Study of LUMIGAN® RC in the Clinical Setting | Biotech Hunter | Biotech Hunter